Skip to main content

Table 5 Summary of adverse events and serious adverse events (all enrolled participants)

From: Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

  Number of individuals (N = 36)
Adverse events -
Total 25 (69.4%)
 Mild 23 (63.9%)
 Moderate 15 (41.7%)
 Severe 5 (13.9%)
Most common adverse events experienced by > 5% of participants -
 Rhinitis 8 (22.2%)
 Diarrhoea 7 (19.4%)
 Pyrexia 6 (16.7%)
 Nasopharyngitis 5 (13.9%)
 Bronchitis 3 (8.3%)
 Gastroenteritis 2 (5.6%)
 Cough 2 (5.6%)
 Vomiting 2 (5.6%)
 Hepatomegaly 2 (5.6%)
 Pharyngitis 2 (5.6%)
 Skin infection 2 (5.6%)
 Pain in extremities 2 (5.6%)
 Headache 2 (5.6%)
 Serious adverse events
Total 3 (8.3%)
 Wound infection 2 (5.6%)
 Streptococcus infection 1 (2.8%)
 Scarlet fever 1 (2.8%)
 EBV infection 1 (2.8%)
 Discontinuations owing to adverse events 0 (0.0%)
  1. EBV: Epstein–Barr virus